Clinical Evaluation of a New Reduced Volume Bowel Preparation

Norgine30 enrolled

Overview

Monocentric, cleansing evaluation pilot study in patients undergoing colonoscopy.

Open prospective pilot monocentric phase II clinical trial evaluating the therapeutic efficacy of a new "Low Dose Bowel Prep" formulation for gut cleansing prior to colonoscopy. Thirty patients admitted to the hospital (inpatients) planned to undergo a complete colonoscopy will have gut cleansing with the "Low Dose Bowel Prep" using a one-step intake mode.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Colonoscopy

Interventions

macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbateDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * male or female, inpatients 18 to 65 years old with indication for complete colonoscopy * the patient's written informed consent must be obtained prior to inclusion * willing and able to complete the entire procedure and to comply with study instructions Exclusion Criteria: * ileus or toxic megacolon * intestinal obstruction or perforation * known of G6PD insufficiency * history of any colonic surgery * ischaemic cardiovascular disease * untreated or uncontrolled arterial hypertension (max \>170mmHg, min \>100mmHg) * renal insufficiency (creating above 45µmol/l) * abnormal laboratory values (clinically significant) for sodium, potassium,chloride, creatinine and hematocrit * cirrhosis of liver (Child-Pugh grade B or C) * females who are pregnant, nursing or planning a pregnancy. Females of child bearing potential not using reliable methods of contraception. * concurrent participation in an investigational drug study or participation within 30 days of study entry * subject has a condition or is in a situation which in the investigators opinion may put the subject at significant risk, may confound the study results or may interfere significantly

Locations (1)

Hôpital Lariboisière, Endoscopy Department

Paris, France

Outcomes

Primary Outcomes

Efficacy measured by a final scoring system i.e., "the overall quality of colonoscopy prep" that will be graded (from A to C) and assessed from the degree of cleansing in a 0 - 4 grade scale for each of the predefined colon areas.

Secondary Outcomes

Stool weight as recorded on the case report form for each stool as from start of gut cleansing (day -1) to the beginning of colonoscopy (day 0).

Amount of fluid removed from the colon during the colonoscopy.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.